Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02956460 · ClinicalTrials.gov registry record · NA

Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses

A NA study of Myopia, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
64
Enrollment target
4
Study locations

NCT02956460 is a NA study of Myopia that has completed, run by CooperVision. The registered enrollment target is 64 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02956460, a NA study of Myopia, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target
4
Study locations

Study Summary

Prospective, multi-center, bilateral, double-masked, randomized, cross-over, daily wear, 1 month dispensing study (2 weeks each lens pair)

Conditions Studied

Interventions

  • DEVICE senofilcon A
  • DEVICE fanfilcon A

Study Locations (4)

California

  • Eric M. White O. D., Inc - San Diego

Florida

  • Golden Vision - Sarasota

Kansas

  • Kannarr Eye Care - Pittsburg

Pennsylvania

  • Nittany Eye Associates - State College

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2016-10-27
Est. Completion 2016-12-14
Phase NA

Sponsor

CooperVision

64 total trials

What the Registry Record Tells You About NCT02956460

The ClinicalTrials.gov registry entry for NCT02956460 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The listed sponsor is CooperVision, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which senofilcon A is the first listed.

NCT02956460 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT02956460 about?

NCT02956460 is a clinical study titled "Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses". Prospective, multi-center, bilateral, double-masked, randomized, cross-over, daily wear, 1 month dispensing study (2 weeks each lens pair)

What is the current status of trial NCT02956460?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2016-10-27. Estimated completion is 2016-12-14.

What conditions does trial NCT02956460 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT02956460?

The interventions under investigation include: senofilcon A (DEVICE), fanfilcon A (DEVICE).

Who is sponsoring clinical trial NCT02956460?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02956460 being conducted?

This trial has 4 study locations across California, Florida, Kansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.